RT Journal Article
SR Electronic
T1 Diagnostic Performance of MRI Radiomics for Classification of Alzheimer’s disease, Mild Cognitive Impairment, and Normal Subjects: A Systematic Review and Meta-analysis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.03.26.23287754
DO 10.1101/2023.03.26.23287754
A1 Shahidi, Ramin
A1 Baradaran, Mansoureh
A1 Asgarzadeh, Ali
A1 Bagherieh, Sara
A1 Tajabadi, Zohreh
A1 Farhadi, Akram
A1 Korani, Setayesh Sotoudehnia
A1 Khalafi, Mohammad
A1 Shobeiri, Parnian
A1 Sadeghsalehi, Hamidreza
A1 Shafieyoun, Arezoo
A1 Yazdanifar, Mohammad Amin
A1 Singhal, Aparna
A1 Sotoudeh, Houman
YR 2023
UL http://medrxiv.org/content/early/2023/03/28/2023.03.26.23287754.abstract
AB Background Alzheimer’s disease (AD) is a debilitating neurodegenerative disease. Early diagnosis of AD and its precursor, mild cognitive impairment (MCI), is crucial for timely intervention and management. Magnetic resonance imaging (MRI) radiomics showed a promising result for diagnosing and classifying AD, and MCI from normal subjects. Thus, we aimed to systematically evaluate the diagnostic performance of the MRI radiomics for this task.Methods and materials A comprehensive search of the current literature was conducted using relevant keywords in PubMed/MEDLINE, Embase, Scopus, and Web of Science databases from inception to October 17, 2022. Original studies discussing the diagnostic performance of MRI Radiomics for the classification of AD, MCI, and normal subjects were included. Method quality was evaluated with the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2), and the Radiomic Quality Score tool (RQS).Results We identified 10 studies that met the inclusion criteria, involving a total of 3446 participants. The overall quality of the included studies was moderate to high. The pooled sensitivity and specificity of MRI radiomics for differentiating AD from normal subjects were 0.8822 (95% CI 0.7888-0.9376), and 0.8849 (95% CI 0.7978-0.9374), respectively. The pooled sensitivity and specificity of MRI radiomics for differentiating MCI from normal subjects were 0.7882 (95% CI 0.6272-0.8917) and 0.7736 (95% CI 0.6480-0.8639), respectively. Also, the pooled sensitivity and specificity of MRI radiomics for differentiating AD from MCI were 0.6938 (95% CI 0.6465-0.7374) and 0.8173 (95% CI 0.6117-0.9270), respectively.Conclusion MRI radiomics has promising diagnostic performance in differentiating AD, MCI, and normal subjects. It can potentially serve as a non-invasive and reliable tool for early diagnosis and classification of AD and MCI.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors